154 related articles for article (PubMed ID: 27879216)
1. Generation of induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia patient carrying a homozygous R486C mutation in CYP7B1 (SPG5).
Höflinger P; Theurer Y; Schüle R; Schöls L; Hauser S
Stem Cell Res; 2016 Sep; 17(2):422-425. PubMed ID: 27879216
[TBL] [Abstract][Full Text] [Related]
2. Generation of induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia patient carrying a homozygous Y275X mutation in CYP7B1 (SPG5).
Hauser S; Höflinger P; Theurer Y; Rattay TW; Schöls L
Stem Cell Res; 2016 Sep; 17(2):437-440. PubMed ID: 27879220
[TBL] [Abstract][Full Text] [Related]
3. Establishment of SPAST mutant induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia (HSP) patient.
Hauser S; Erzler M; Theurer Y; Schuster S; Schüle R; Schöls L
Stem Cell Res; 2016 Nov; 17(3):485-488. PubMed ID: 27789400
[TBL] [Abstract][Full Text] [Related]
4. CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5.
Goizet C; Boukhris A; Durr A; Beetz C; Truchetto J; Tesson C; Tsaousidou M; Forlani S; Guyant-Maréchal L; Fontaine B; Guimarães J; Isidor B; Chazouillères O; Wendum D; Grid D; Chevy F; Chinnery PF; Coutinho P; Azulay JP; Feki I; Mochel F; Wolf C; Mhiri C; Crosby A; Brice A; Stevanin G
Brain; 2009 Jun; 132(Pt 6):1589-600. PubMed ID: 19439420
[TBL] [Abstract][Full Text] [Related]
5. Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial.
Schöls L; Rattay TW; Martus P; Meisner C; Baets J; Fischer I; Jägle C; Fraidakis MJ; Martinuzzi A; Saute JA; Scarlato M; Antenora A; Stendel C; Höflinger P; Lourenco CM; Abreu L; Smets K; Paucar M; Deconinck T; Bis DM; Wiethoff S; Bauer P; Arnoldi A; Marques W; Jardim LB; Hauser S; Criscuolo C; Filla A; Züchner S; Bassi MT; Klopstock T; De Jonghe P; Björkhem I; Schüle R
Brain; 2017 Dec; 140(12):3112-3127. PubMed ID: 29126212
[TBL] [Abstract][Full Text] [Related]
6. Generation of optic atrophy 1 patient-derived induced pluripotent stem cells (iPS-OPA1-BEHR) for disease modeling of complex optic atrophy syndromes (Behr syndrome).
Hauser S; Schuster S; Theurer Y; Synofzik M; Schöls L
Stem Cell Res; 2016 Sep; 17(2):426-429. PubMed ID: 27879217
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of Taiwanese patients with Hereditary spastic paraplegia type 5.
Chou CT; Soong BW; Lin KP; Tsai YS; Jih KY; Liao YC; Lee YC
Ann Clin Transl Neurol; 2020 Apr; 7(4):486-496. PubMed ID: 32202070
[TBL] [Abstract][Full Text] [Related]
8. Induced pluripotent stem cells (iPSCs) derived from cerebrotendinous xanthomatosis (CTX) patient's fibroblasts carrying a R395S mutation.
Höflinger P; Hauser S; Theurer Y; Weißenberger S; Wilke C; Schöls L
Stem Cell Res; 2016 Sep; 17(2):433-436. PubMed ID: 27879219
[TBL] [Abstract][Full Text] [Related]
9. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying a L150P mutation in PSEN-1.
Tubsuwan A; Pires C; Rasmussen MA; Schmid B; Nielsen JE; Hjermind LE; Hall V; Nielsen TT; Waldemar G; Hyttel P; Clausen C; Kitiyanant N; Freude KK; Holst B
Stem Cell Res; 2016 Jan; 16(1):110-2. PubMed ID: 27345792
[TBL] [Abstract][Full Text] [Related]
10. Exome Sequencing Reveals a Novel Homozygous Frameshift Mutation in the CYP7B1 Gene in a Japanese Patient with SPG5.
Nan H; Shimozono K; Ichinose Y; Tsuchiya M; Koh K; Hiraide M; Takiyama Y
Intern Med; 2019 Mar; 58(5):719-722. PubMed ID: 30333426
[TBL] [Abstract][Full Text] [Related]
11. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying an A79V mutation in PSEN1.
Li T; Pires C; Nielsen TT; Waldemar G; Hjermind LE; Nielsen JE; Dinnyes A; Hyttel P; Freude KK
Stem Cell Res; 2016 Mar; 16(2):229-32. PubMed ID: 27345973
[TBL] [Abstract][Full Text] [Related]
12. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying a M146I mutation in PSEN1.
Li T; Pires C; Nielsen TT; Waldemar G; Hjermind LE; Nielsen JE; Dinnyes A; Holst B; Hyttel P; Freude KK
Stem Cell Res; 2016 Mar; 16(2):334-7. PubMed ID: 27345998
[TBL] [Abstract][Full Text] [Related]
13. Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5.
Marelli C; Lamari F; Rainteau D; Lafourcade A; Banneau G; Humbert L; Monin ML; Petit E; Debs R; Castelnovo G; Ollagnon E; Lavie J; Pilliod J; Coupry I; Babin PJ; Guissart C; Benyounes I; Ullmann U; Lesca G; Thauvin-Robinet C; Labauge P; Odent S; Ewenczyk C; Wolf C; Stevanin G; Hajage D; Durr A; Goizet C; Mochel F
Brain; 2018 Jan; 141(1):72-84. PubMed ID: 29228183
[TBL] [Abstract][Full Text] [Related]
14. Clinical and genetic analysis of Taiwanese patients with hereditary spastic paraplegia type 5.
Lan MY; Yeh TH; Chang YY; Kuo HC; Sun HS; Lai SC; Lu CS
Eur J Neurol; 2015 Jan; 22(1):211-4. PubMed ID: 24641183
[TBL] [Abstract][Full Text] [Related]
15. SPG5 and multiple sclerosis: clinical and genetic overlap?
Criscuolo C; Carbone R; Lieto M; Peluso S; Guacci A; Filla A; Quarantelli M; Lanzillo R; Morra VB; De Michele G
Acta Neurol Scand; 2016 Jun; 133(6):410-4. PubMed ID: 26370385
[TBL] [Abstract][Full Text] [Related]
16. Hereditary spastic paraparesis due to SPG5/CYP7B1 mutation with potential therapeutic implications.
Pérez-Torre P; García Galloway E; López-Sendón Moreno JL
Neurologia (Engl Ed); 2023; 38(9):710-711. PubMed ID: 37858890
[No Abstract] [Full Text] [Related]
17. Two novel CYP7B1 mutations in Italian families with SPG5: a clinical and genetic study.
Criscuolo C; Filla A; Coppola G; Rinaldi C; Carbone R; Pinto S; Wang Q; de Leva MF; Salvatore E; Banfi S; Brunetti A; Quarantelli M; Geschwind DH; Pappatà S; De Michele G
J Neurol; 2009 Aug; 256(8):1252-7. PubMed ID: 19363635
[TBL] [Abstract][Full Text] [Related]
18. White matter lesions in spastic paraplegia with mutations in SPG5/CYP7B1.
Biancheri R; Ciccolella M; Rossi A; Tessa A; Cassandrini D; Minetti C; Santorelli FM
Neuromuscul Disord; 2009 Jan; 19(1):62-5. PubMed ID: 19187859
[TBL] [Abstract][Full Text] [Related]
19. Mining for Oxysterols in
Meljon A; Crick PJ; Yutuc E; Yau JL; Seckl JR; Theofilopoulos S; Arenas E; Wang Y; Griffiths WJ
Biomolecules; 2019 Apr; 9(4):. PubMed ID: 31013940
[TBL] [Abstract][Full Text] [Related]
20. Clinical phenotype variability in patients with hereditary spastic paraplegia type 5 associated with CYP7B1 mutations.
Arnoldi A; Crimella C; Tenderini E; Martinuzzi A; D'Angelo MG; Musumeci O; Toscano A; Scarlato M; Fantin M; Bresolin N; Bassi MT
Clin Genet; 2012 Feb; 81(2):150-7. PubMed ID: 21214876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
